SKU : MC541930
CAS Number : 2222-07-3
Molecular Formula : C30H42O7 | Molecular Weight : 514.65
Synonyms : Elatericin B;JSI-124;NSC-521777
Quote RequestPurity | NLT 98% |
---|---|
Storage | at 20ºC 2 years |
* The above information is for reference only.
* If the product has intellectual property rights, a license granted is must or contact us.
Chemical Name | Cucurbitacin I |
---|---|
CAS Number | 2222-07-3 |
MDL Number | MFCD09971044 |
Molecular Formula | C30H42O7 |
Molecular Weight | 514.65 |
Synonyms | Elatericin B;JSI-124;NSC-521777 |
Cucurbitacin I is a natural selective inhibitor of JAK2/STAT3, with potent anti-cancer activity. In Vitro: Exposure of the COLO205 cells to Cucurbitacin I significantly decreases cell viability. The anticancer activity of Cucurbitacin I is accomplished by downregulating p-STAT3 and MMP-9 expression[1]. PE-induced cell enlargement and upregulation of ANF and β-MHC are significantly suppressed by pretreatment of the cardiomyocytes with Cucurbitacin I. Notably, Cucurbitacin I also impaires connective tissue growth factor (CTGF) and MAPK signaling, pro-hypertrophic factors, as well as TGF-β/Smad signaling, the important contributing factors to fibrosis[2]. Incubation of the Seax cell line with the Jak/Stat3 inhibitor Cucurbitacin I result in a time- and concentration-dependent decrease of P-Stat3 and Stat3. In freshly isolated Sz cells (n=3), Cucurbitacin I induces a concentration-dependent decrease in Stat3 expression whereas P-Stat3 is undetectable. Finally, incubation of freshly isolated Sz cells (n=4) with 30 μM Cucurbitacin I for 6 hours induces apoptosis in the large majority (73-91%) of tumor cells[3]. In Vivo: No major side effects are noted throughout the study. It is shown that average tumor volumes at the end of the study are as follows: control, 616 mm3 (±130); CQ, 580 mm3 (±107); Cucurbitacin I, 346mm3 (±79); and combination, 220mm3 (±62). The differences in tumor volume between the Cucurbitacin I and control, combination and control, and combination and Cucurbitacin I arms are significant. Furthermore, combination-treated tumors exhibit a significantly lower average tumor weight at study termination than the control. Moreover, there was no effect on the body weights of mice[4].
© Copyright 2015-2024 Hangzhou MolCore BioPharmatech Co.,Ltd. All rights reserved.